Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Enzon Pharmaceuticals Inc. (ENZND) had Normalized Pre-Tax Income of $-3.39M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-5.53M |
|
-- |
|
-- |
|
$5.31M |
|
$-5.31M |
|
$1.92M |
|
$-3.39M |
|
|
Normalized Pre-Tax Income |
$-3.39M |
$-3.41M |
|
$-3.41M |
|
$-3.41M |
|
$-3.41M |
|
$-5.31M |
|
$-5.31M |
|
74.22M |
|
74.22M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$42.81M |
|
-- |
|
-- |
|
$42.81M |
|
$0.73M |
|
-- |
|
-- |
|
$0.73M |
|
$-2.52M |
|
$42.08M |
|
$42.08M |
|
74.22M |
|
| Cash Flow Statement Financials | |
$-3.01M |
|
-- |
|
$-1.27M |
|
$46.86M |
|
$42.57M |
|
$-4.29M |
|
-- |
|
-- |
|
$-1.27M |
|
| Fundamental Metrics & Ratios | |
58.57 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.01M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
135.01% |
|
-8.10% |
|
-7.96% |
|
-8.10% |
|
$0.57 |
|
$-0.04 |
|
$-0.04 |
|